相关实验视频

Updated: Jul 23, 2026

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

组织多抗原作为一个非侵入性膀癌症生物标志物

Neeraj Kumar Fuloria¹, Kamal Narain², Anupam Biswas³

¹Faculty of Pharmacy, AIMST university, Bedong, Kedah 08100, Malaysia.

Clinica chimica acta; international journal of clinical chemistry

|January 15, 2026

概括

组织多抗原 (TPA) 显示出对非侵入性膀癌症监测的承诺. 标准化是其临床应用的关键,特别是在多标记器算法中,以提高诊断准确性和患者管理.

科学领域:

生物化学生物化学
在瘤学瘤学.
临床诊断临床诊断临床诊断

背景情况:

组织多抗原 (TPA) 是一种非侵入性生物标志物,来源于细胞激素8,18和19.
TPA显示出非侵入性膀癌监测的潜力,但标准化挑战阻碍了临床使用.

研究的目的:

审查TPA的分子生物学及其临床实验室实践.
强调分析标准化,分析前协调和TPA的诊断算法.

主要方法:

叙述性审查侧重于TPA的分析和临床方面.
在非肌肉侵入性膀癌 (NMIBC) 和肌肉侵入性膀癌 (MIBC) 中分析TPA性能.

主要成果:

在高风险NMIBC的优化方案中,尿TPA显示出高灵敏度 (80-85%) 和特异性 (97%).
单克隆化学发光试验显示,试验内部变化很小 (<5%),但方法间偏差很大 (20-30%).
与细胞学和免疫细胞化学集成的TPA产生了曲线下的诊断面积>0.90.0.

结论:

对于分区特定监测,特别是多标记算法中,TPA是有价值的,而不是作为独立测试.
标准化预分析操作 (符合IFCC),实验室特定的切线和外部质量保证对于临床实施至关重要.
需要对成本效益和减少TPA导向囊镜的进一步研究.

关键词:

生物标志物的标准化标准化.膀癌是一种癌症.临床实验室医学临床实验室医学预分析性协调预分析性协调组织多抗原抗原.

更多相关视频

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Evaluation of the Efficacy of the H. pylori Protein HP-NAP as a Therapeutic Tool for Treatment of Bladder Cancer in an Orthotopic Murine Model

Published on: May 29, 2015

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

A Murine Orthotopic Bladder Tumor Model and Tumor Detection System

Published on: January 12, 2017

相关概念视频

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.